Literature DB >> 11579084

A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion.

G Chen1, L Paka, Y Kako, P Singhal, W Duan, S Pillarisetti.   

Abstract

Mesangial expansion is a key feature in the pathogenesis of numerous renal diseases involving the glomerulus. Studies indicate that mutations in apolipoprotein E (apoE) might independently contribute to kidney dysfunction. Although the role of apoE as an atheroprotective molecule is well established, its role in kidney is unclear. In this study, we sought to explore whether apoE has a protective function in kidney. Northern blotting and reverse transcriptase-polymerase chain reaction showed apoE expression in kidney, and mesangial cell is a major source of apoE in kidney. In the kidneys of 14-16-month-old apoE-null mice, hematoxylin-eosin (HE) staining revealed increased mesangial cell proliferation and matrix formation compared with wild type mice or apoB-overexpressing mice, which have elevated plasma cholesterol and triglycerides. These data suggest that lack of apoE, rather than hyperlipidemia, contributes to increased mesangial expansion. We isolated mesangial cells from mouse kidney and determined the effect of apoE on cell growth. ApoE (E3, 10 microg/ml) completely inhibited serum, platelet-derived growth factor (10 ng/ml), as well as low density lipoprotein-induced mesangial cell proliferation. Among the three isoforms, E3 was found to be most effective in inhibiting mesangial cell proliferation. ApoE did not show any cytotoxic effect, and moreover, inhibited mesangial cell apoptosis induced by oxidized low density lipoprotein. These data suggest that apoE regulates growth as well as survival of mesangial cells. We previously showed that apoE induces matrix heparan sulfate proteoglycan (HSPG) in vascular cells, which has an antiproliferative effect. Similarly, apoE induced the mesangial matrix HSPG. Perlecan is the major HSPG of mesangial matrix and subendothelial space, and consistent with this, blockade of perlecan reversed the antiproliferative effect of apoE. Immunohistochemistry revealed reduced staining of perlecan in kidney from apoE-null mice. Because the loss of anionic HSPG in the basement membrane and mesangial matrix is associated with disruption of filtration barrier, these data suggest a novel role for kidney apoE in preserving the filtration barrier. In summary, apoE has a protective function in kidney as an autocrine regulator of mesangial expansion and kidney function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579084     DOI: 10.1074/jbc.M104879200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Identification of candidate disease genes by EST alignments, synteny, and expression and verification of Ensembl genes on rat chromosome 1q43-54.

Authors:  Ursula Vitt; Darryl Gietzen; Kristian Stevens; Jim Wingrove; Shanya Becha; Sean Bulloch; John Burrill; Narinder Chawla; Jennifer Chien; Matthew Crawford; Craig Ison; Liam Kearney; Mary Kwong; Joe Park; Jennifer Policky; Mark Weiler; Renee White; Yuming Xu; Sue Daniels; Howard Jacob; Michael I Jensen-Seaman; Jozef Lazar; Laura Stuve; Jeanette Schmidt
Journal:  Genome Res       Date:  2004-04       Impact factor: 9.043

2.  Genetic diversity of the apolipoprotein E gene and diabetic nephropathy: a meta-analysis.

Authors:  Yang Li; Kefu Tang; Zhao Zhang; Ming Zhang; Zhen Zeng; Zangdong He; Lin He; Chunling Wan
Journal:  Mol Biol Rep       Date:  2010-02-24       Impact factor: 2.316

3.  Inhibitor of differentiation 3, a transcription factor, regulates hyperlipidemia-associated kidney disease.

Authors:  Dominika Nackiewicz; Paromita Dey; Barbara Szczerba; Saleh Mohammad; Jennifer L Kaplan; Coleen A McNamara; Umesh S Deshmukh; Harini Bagavant
Journal:  Nephron Exp Nephrol       Date:  2014-05-16

4.  Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies.

Authors:  Aleksey Nakorchevsky; Johannes A Hewel; Sunil M Kurian; Tony S Mondala; Daniel Campbell; Steve R Head; Christopher L Marsh; John R Yates; Daniel R Salomon
Journal:  J Am Soc Nephrol       Date:  2010-01-21       Impact factor: 10.121

5.  Apolipoprotein E polymorphism in hemodialyzed patients and healthy controls.

Authors:  Jaroslav A Hubacek; Silvie Bloudickova; Ruzena Kubinova; Hynek Pikhart; Ondrej Viklicky; Martin Bobak
Journal:  Biochem Genet       Date:  2009-06-30       Impact factor: 1.890

6.  Genetic disruption of Npr1 depletes regulatory T cells and provokes high levels of proinflammatory cytokines and fibrosis in the kidneys of female mutant mice.

Authors:  Venkateswara Reddy Gogulamudi; Indra Mani; Umadevi Subramanian; Kailash N Pandey
Journal:  Am J Physiol Renal Physiol       Date:  2019-04-03

7.  Mechanisms of acute kidney injury induced by experimental Lonomia obliqua envenomation.

Authors:  Markus Berger; Lucélia Santi; Walter O Beys-da-Silva; Fabrício Marcus Silva Oliveira; Marcelo Vidigal Caliari; John R Yates; Maria Aparecida Ribeiro Vieira; Jorge Almeida Guimarães
Journal:  Arch Toxicol       Date:  2014-05-06       Impact factor: 5.153

8.  Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.

Authors:  Sanjeev Sethi; Jeffrey D Gamez; Julie A Vrana; Jason D Theis; H Robert Bergen; Peter F Zipfel; Ahmet Dogan; Richard J H Smith
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

Review 9.  Pathogenesis of ovarian cancer: clues from selected overexpressed genes.

Authors:  Ie-Ming Shih; Ben Davidson
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

10.  Association of APOE polymorphism with chronic kidney disease in a nationally representative sample: a Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study.

Authors:  Audrey Y Chu; Rulan S Parekh; Brad C Astor; Josef Coresh; Yvette Berthier-Schaad; Michael W Smith; Alan R Shuldiner; Wen Hong L Kao
Journal:  BMC Med Genet       Date:  2009-10-23       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.